Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19-and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone. The therapy success rate for T-cell acute lymphoblastic leukemia (T-ALL) is significantly lower than that for precursor B-cell acute lymphoblastic leukemia. Relapse of the disease and therapy-related toxicity are the most common causes of unfavorable outcome. Therefore, accurate stratification is essential to avoid both undertreatment and overtreatment of patients. T-cell receptor gene-based minimal residual disease (MRD) quantification is so far the only most clinically relevant prognostic factor in T-ALL. 1,2 However, as it is laborious and time consuming, there is an urgent need for identification of novel prognostic factors in T-ALL.
Hypermethylation of CpG islands is a recognized mechanism of inactivation of tumor suppressor genes, associated with neoplastic transformation. Different cancer types are characterized by unique methylation patterns, which could be useful for diagnostic and prognostic purposes. 3 However, methylation pattern in T-ALL has only been analyzed by one group so far 4 and their results need to be verified in larger cohorts of patients. One of the currently most intriguing questions arising in epigenetics concerns the existence of a CpG island methylator phenotype (CIMP). 5 As proposed by Toyota et al., patients might be classified into two distinct groups, presenting with different clinical, histological and molecular characteristics, based on the number of hypermethylated genes: CIMP þ , with many hypermethylated genes, and CIMP À , with a low number of hypermethylated genes. To date, there has only been one study addressing the CIMP phenomenon in T-ALL. 4 Here, we report for the first time the CpG islands methylation status of 20 genes determined in T-ALL pediatric patients, healthy children and in normal thymic cells. In our T-ALL cohort we analyzed the methylation status of 15 genes reported by others to be hypermethylated in T-ALL 4 and 5 additional genes, suspected or newly identified factors in tumorigenesis of this disease. This was to determine if the methylation pattern of these genes is characteristic to T-ALL or related to developmental stages of normal thymocytes. In addition, we analyzed the obtained results in regard to current findings on CIMP in T-ALL and in other tumors. 6 To assess the methylation patterns, we performed methylation-specific PCR (MS-PCR) with the use of bisulfite-modified DNA, extracted from bone marrow samples collected at diagnosis from 61 pediatric T-ALL patients, and, as controls ,   T19  T291  T413  T684  T832  T60  T157  T418  T384  T70  T288  T168  T587   T566   T986   T170  T381  T67  T310  T221  T120  T330  T920  T388  T398  T314  T319  T207  T682  T245  T173  T83  T630  T131  T116  T240  T929  T134.1   T1   T1200  T1164  T644  T1125  T510  T622  T11.1  T73  T848  T62  T601  T1117  T473  T252  T360  T1033  T1138  T501  T304  T280  T283  T133 Color Key Figure 1 Unsupervised patient hierarchical clustering (complete linkage method) and the resulting heat map representing the methylation Z-score value for particular genes in the analyzed patients. PTPN2, C/EBPA, p16/CDKN2A, ASPP1, LATS1, BCL11B, FBXW7, NFkB, CDKN1B/p27 KIP1 RB1 and p73 are not presented on the heat map as their methylation status was equal for all the patients and controls. Two clusters identified are marked by red line. The clustering was performed with use of R software package (http://www.r-project.org/).
11 healthy children and thymic cells, pooled from 5 children undergoing heart surgery, otherwise healthy. The genes selected for CpG methylation analysis included SYK, CDH1, ADAMTS5, NES1, FBXW7, p16/CDKN2A, p73, ASPP1, NFkB, DIABLO, sFRP1, WIF1, CDKN1B/p27 KIP1 CDKN1c/p57 KIP2 RB1, LATS1, BCL11B, PTPN2, PHF6 and C/EBPA. Five of these genes have not been previously studied for methylation in T-ALL (namely FBXW7, NFkB, RB1, BCL11B and PHF6); PTPN2 was previously analyzed in only a small cohort of T-ALL patients. 7 The analyzed genes have been selected based on their involvement in T-ALL pathogenesis as reported by others. 4, [8] [9] [10] [11] Primer sequences are presented in Supplementary Table 1 . On the basis of the number of hypermethylated genes patients were divided into CIMP þ and CIMP À groups. Existence of two different patterns of methylation in the study group was further confirmed by computational clustering (Figure 1 ). To provide insights into clinical significance of CIMP þ /CIMP À in T-ALL, we related our findings to traditional risk group assessment criteria, namely age at diagnosis, white blood cell count at diagnosis, initial response to prednisone and bone marrow morphology at day 15 and 33, as well as occurrence of relapse and death. Additionally, methylation patterns were correlated with ALL IC-BMF 2002 risk groups and with NOTCH1 and FBXW7 mutation status.
An average of 2.4 hypermethylated loci per patient was observed in the study group (frequency distribution is presented in Supplementary Table 2 ). In contrast, none of the analyzed genes were hypermethylated in healthy children and thymic subsets, with exception of the p73 gene, which was uniformly hypermethylated in healthy children, thymic cells and all patients. In all, 10 genes were uniformly hypomethylated in healthy children, normal thymic cells and patients (namely, PTPN2, C/EBPA, p16/CDKN2A, ASPP1, LATS1, BCL11B, FBXW7, NFkB, CDKN1B/p27 KIP1 and RB1). All five genes analyzed for promoter methylation in T-ALL for the first time in the present study, with the exception of PHF6, showed no evidence of hypermethylation ( Table 1) . As these genes have been previously reported to contribute to T-ALL through deletional or mutational inactivation, our results confirm the existence of only one preferential mechanism for gene inactivation in malignancies. 4, 9 We have found five genes to be as frequently hypermethylated in our cohort as reported by others (CDH1, ADAMTS5, NES1, sFRP1 and PTPN2), 4, 7 and eight genes less frequently hypermethylated than previously reported (C/EBPA, SYK, p16/ CDKN2A, ASPP1, DIABLO, WIF1 and CDKN1C/p57 KIP2 LATS1) 4, 12 (Table 1 ). These results indicate that methylation frequency might differ significantly between studies. This is in line with findings of methylation studies carried out in other diseases, especially in colorectal cancer, 13 which is the most comprehensively studied malignancy for DNA methylation, and might be regarded as a model of epigenetic events in tumorigenesis. 14 We suggest that methylation frequency discrepancies could be attributed to age differences between analyzed T-ALL groups that is, reflecting T-ALL-specific age-dependent methylation patterns. However, as the majority of primers applied in our study was different from those used by Roman-Gomez et al., 4 it seems more likely that different CpG spots included in primer sequences display different methylation status within a CpG island. These findings illustrate that MS-PCR, as a method, does not allow for the study of differential methylation status within a CpG island and can Table 1 Methylation frequency of particular loci observed in the present study and as found by Roman-Gomez et al., 4 Roman-Gomez et al., 10 Kleppe et al., 7 Terriou et al., 12 and Batova et al.
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Letters to the Editor only be applied as a qualitative method for preliminary methylation assessment. In order to distinguish CIMP þ /CIMP À groups, we divided our cohort into two subgroups according to the guidelines used by Roman-Gomez et al.:
4 a CIMP À group, with two or less hypermethylated genes (32/61; 53%), and a CIMP þ group, characterized by three or more hypermethylated genes (39/61; 47%). For the purpose of CIMP þ /CIMP À classification and computational clustering the p73 gene, uniformly hypermethylated in all patients and controls, as well as PTPN2, C/EBPA, p16/CDKN2A, ASPP1, LATS1, BCL11B, FBXW7, NFkB, CDKN1B/p27 KIP1 and RB1 genes, uniformly hypomethylated in all patients and controls were excluded from the analysis. Computational clustering of patients, based on similarities in methylation patterns in the analyzed samples, confirmed the existence of two groups, which correlated with CIMP þ / CIMP À groups established manually (Po0.0001), (Figure 1 ). We therefore confirm the CIMP þ /CIMP À delineating threshold proposed by Roman-Gomez et al., 4 even though the total number of the analyzed genes differed between studies (20 genes in the present study vs 27 by Roman-Gomez et al.). Nevertheless, identification of CIMP in T-ALL might have to be interpreted with caution. Weisenberger et al. 6 suggested that markers chosen for CIMP screening should be characterized by a bimodal distribution of the number of hypermethylated genes in a studied population. However, it is difficult to assess the actual impact of the lack of bimodal distribution in our cohort (Supplementary Table 2 ) on the accuracy of CIMP þ /CIMP À identification, owing to extremely limited data on CpG islands methylation in T-ALL. CIMP has been previously established to be an independent factor predicting poor outcome and higher relapse risk in T-ALL. 4 In order to verify this observation, we analyzed the correlation between the methylation status and clinical data, traditionally used for risk group assessment, and with mutation status of NOTCH1 and FBXW7 genes. We found no correlation between CIMP þ and age at diagnosis, white blood cell counts at diagnosis, prednisone response, bone marrow morphology at days 15 and 33, occurrence of relapse and death, as well as ALL IC-BMF 2002 risk group classification nor NOTCH1 and FBXW7 mutation status. Correlation of CIMP with MRD data was not possible, owing to limited amount of biological material available for the study. We are aware that MRD results currently providing the most clinically relevant prognostic information might be extremely useful to answer the question on the potential prognostic significance of the CIMP phenomenon and its correlation with treatment response and outcome. We therefore advocate the use of MRD information, whenever possible, in the studies aimed at verification of clinical utility of CIMP phenomenon in ALL.
In conclusion, we demonstrate for the first time that the pattern of CpG islands methylation differs in childhood T-ALL as compared with normal thymic subsets, hence is specific to tumorigenesis and not to normal development of thymocytes. We also show that the pattern of methylation discriminates between two groups of patients, which might possibly prove to have clinical implications. Our results confirm the existence of CIMP phenomenon in childhood T-ALL and provide further insights into the role of hypermethylation in leukemogenesis.
Recently, next generation sequencing technology has been applied to discover tumor-specific mutations in acute myeloid leukemia (AML) genomes. 1 After the finding of recurrent mutations in the enzyme isocitrate dehydroxygenase 1 (IDH1) in AML, 2 two studies recently reported the identification of somatic mutations in the DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A) gene in adult AML cases. 3, 4 Ley et al.
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reported the presence of DNMT3A mutations in 22% of de novo adult AML cases, after the discovery of this mutation by sequencing a whole AML genome. They found that DNMT3A mutations were highly associated with cytogenetically normal (CN)-AML (37% (44 of 120) CN-AML cases). Yan et al. 4 detected DNMT3A mutations by sequencing the complete coding region of the genome (exome sequencing) of nine AML-M5 samples. They found that these mutations were restricted to the myelomonocytic (French-American-British (FAB)-M4) and monocytic (FAB-M5) AML subtypes, presenting in 13.6 and 20.5% of these cases, respectively. DNMT3A mutations were localized in the methyltransferase and the plant homeo domain fingers, and impaired DNMT3A methyltransferase activity, or altered histone H3 affinity in vitro. Both studies reported a poor clinical outcome for patients with DNMT3A-mutated AML. 3, 4 We identified the presence of a somatic heterozygous R882C mutation in the DNMT3A gene by performing exome sequencing of a pediatric AML case and confirmed this mutation by Sanger sequencing (Figure 1 ). This index case concerned an 8-year-old boy with a CN-AML of the FAB-M1 subtype, who is currently in continuous complete remission 3.6 years after diagnosis, following treatment according to the AML MRC15-protocol. Furthermore, we identified a Wilms tumor 1 (WT1) R394W mutation in this patient, resulting from a missense mutation in exon 9, which was known to be present from previous screening for molecular mutations. This case was also characterized by a large insertion/deletion in WT1 exon 7 and an internal tandem duplication in the FLT3 gene ( Table 1) .
As data on DNMT3A mutations in pediatric AML were not yet available, we subsequently screened cDNA of a large representative pediatric AML series (n ¼ 140; including 34 FAB-M4 and 27 FAB-M5 cases, and including 46 CN-AML cases) from Figure 1 Sequence chromatograms of the DNMT3A mutations detected in the pediatric AML index case and the OCI-AML3 cell line. A heterozygous mutation (C4T), changing arginine into cysteine at codon 882, is present in the pediatric AML index case and the OCI-AML3 cell line. The germline sample of the index case did not harbor this mutation. Mutated nucleotides are indicated by arrows.
